We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,040.00
Bid: 1,036.00
Ask: 1,040.00
Change: 2.00 (0.19%)
Spread: 4.00 (0.39%)
Open: 1,060.00
High: 1,060.00
Low: 1,022.00
Yest. Close: 1,038.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Oxford Biomedica sees swing to FY profit on Covid vaccine hopes

Thu, 17th Sep 2020 07:01

(Sharecast News) - Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.
The company, which is pinning its hopes on the AZD1222 trial treatment, said the drug could lift revenues by more than £10m "subject to successful scale up and regulatory approval ... early in the fourth quarter of 2020".

Interim operating losses before interest, tax, depreciation and amortisation came in at £0.4m compared with a loss of £1.4m a year ago. Revenue rose to £34m from £32.1m.

AstraZeneca has paid the gene and cell therapy firm $15m upfront to reserve manufacturing capacity at its plant to mass produce its vaccine candidate.

Oxford Biomedica joined forces with AstraZeeneca in May to produce the vaccine and earlier this month said it could get an extra $35m plus other costs until the end of 2021 under a new 18-month deal. The vaccine will be produced in three suites in the company's Oxbox manufacturing centre.

More News

UPDATE 2-EU demands immediate access to UK-made vaccines in AstraZeneca legal battle

* EU demands faster deliveries in first hearing of legal case* AstraZeneca says lower supplies not in breach of contract* EU, UK vie for doses, Astra has under-delivered to both* Next hearings on May 26, EU seeks verdict before end of June (recast...

28 Apr 21 09:23

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

16 Apr 21 09:49

Oxford Biomedica swings to EBITDA profit

(Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to £87.7m.

15 Apr 21 09:02

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

15 Apr 21 09:00

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

8 Apr 21 16:05

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

6 Apr 21 08:19

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.

6 Apr 21 08:08

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

6 Apr 21 07:53

EU rebuffs UK calls to ship AstraZeneca COVID vaccines from Europe

By Francesco GuarascioBRUSSELS, March 21 (Reuters) - The European Union is rebuffing British government calls to ship AstraZeneca COVID-19 vaccines produced in a factory in the Netherlands, an EU official said on Sunday.Former EU member Britain ha...

21 Mar 21 20:57

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Sanofi to terminate haemophilia development pact with Oxford Biomedica

19 Mar 21 10:29

Oxford Biomedica says Sanofi pulling out of haemophilia project

(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.

19 Mar 21 07:50

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

3 Feb 21 13:56

UPDATE 1-EU holds out for more after AstraZeneca offered 8 mln extra COVID-19 shots

* Astra had committed to at least 80 mln shots in Q1* EU funded two UK plants under deal with Astra - sources* Astra says UK has priority for doses produced there (Adds detail, background)By Francesco Guarascio and Sabine SieboldBRUSSELS, Jan 29 (Re...

29 Jan 21 09:11

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

18 Jan 21 17:18

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

8 Jan 21 09:40

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.